K. Lee

发表

O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

David Cunningham, G. Bodoky, D. Cunningham, 2014 .

A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report.

Chiun Hsu, K. Yeh, A. Cheng, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.

K. Propert, M. Green, S. Graziano, 1990, Medical and pediatric oncology.

Phase II study of genexol (paclitaxel) and carboplatin as first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC).

K. Lee, N. Lee, J. Won, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study

Chiun Hsu, A. Cheng, Ying-Chun Shen, 2008 .

P102 A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI

Hyung-Lae Kim, Y. Min, J. Cheong, 2009 .

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.

M. Scheulen, H. Richly, F. Fleischer, 2010 .

Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer.

H. J. Kim, S. Lee, J. Moon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial.

B. Mirakhur, A. Wang-Gillam, K. Lee, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.

M. Scheulen, H. Richly, K. Mross, 2010 .